Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A

Attarian, ShahramVallat, Jean-MichelMagy, LaurentFunalot, BenoîtGonnaud, Pierre-MarieLacour, ArnaudPéréon, YannDubourg, OdilePouget, JeanMicallef, JoëlleFranques, JérômeLefebvre, Marie-NoëlleGhorab, KarimaAl-Moussawi, MahmoudTiffreau, VincentPreudhomme, MargueriteMagot, ArmelleLeclair-Visonneau, LaurèneStojkovic, TanyaBossi, LauraLehert, PhilippeGilbert, WalterBertrand, VivianeMandel, JonasMilet, AudeHajj, RodolpheBoudiaf, LamiaScart-Grès, CatherineNabirotchkin, SergueiGuedj, MickaelChumakov, IlyaCohen, Daniel2016-08-092016Attarian, S., J. Vallat, L. Magy, B. Funalot, P. Gonnaud, A. Lacour, Y. Péréon, et al. 2016. “Erratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1A.” Orphanet Journal of Rare Diseases 11 (1): 92. doi:10.1186/s13023-016-0463-6. http://dx.doi.org/10.1186/s13023-016-0463-6.1750-1172http://nrs.harvard.edu/urn-3:HUL.InstRepos:27822332en-USErratum to: An exploratory randomised double-blind and placebo-controlled phase 2 study of a combination of baclofen, naltrexone and sorbitol (PXT3003) in patients with Charcot-Marie-Tooth disease type 1AJournal Article2016-08-0910.1186/s13023-016-0463-6